by Ellie Lampton | Dec 5, 2023
In a study of more than 2.4 million children under the age of 5, new research shows a significant increase in the rate of first-time speech delay diagnoses after July 2020. Today Truveta announced new research published in JAMA Pediatrics exploring the incidence of...
by Ellie Lampton | Dec 4, 2023
BELLEVUE, WA. – December 4, 2023 – Truveta, the company with a mission of saving lives with data, welcomes its first member from the life science industry to its Board of Directors. The Truveta Board of Directors ensures the data and analytics company is operating in...
by Ellie Lampton | Nov 27, 2023
In the first comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data, Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15%...
by Ellie Lampton | Nov 8, 2023
With more than 56.6 million clinical observations from more than 2.7 million echocardiogram reports and growing, Truveta is the market leader in real-world data for cardiovascular research. BELLEVUE, Wash. – November 8, 2023 – Today Truveta announced the availability...
by Ellie Lampton | Oct 23, 2023
Bellevue, WASH. – October 23, 2023 – Truveta announced today that it is partnering with more than 50 organizations in life sciences, healthcare, government, academic medical centers, and research institutes to study safety and effectiveness, improve patient care and...
